A study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ influenza vaccine GSK3206641A administered in adults 18 to 64 years of age and 65 years of age and older

Trial Identifier: 209671
Sponsor: GlaxoSmithKline
Start Date: March 2021
Primary Completion Date: September 2022
Study Completion Date: September 2022
Condition: Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, Georgia Stockbridge, Georgia, United States, 30281
United States, Idaho Meridian, Idaho, United States, 83642
United States, North Carolina Cary, North Carolina, United States, 27518
United States, North Carolina Wilmington, North Carolina, United States, 28401
United States, Ohio Cleveland, Ohio, United States, 44122
United States, South Carolina Mt. Pleasant, South Carolina, United States, 29464
United States, Texas Houston, Texas, United States, 77081
United States, Utah West Jordan, Utah, United States, 84088